In this thesis, we investigate how AXIN1, the central scaffold of the β-catenin destruction complex, regulates assembly and function of this complex in healthy cells, and how disease-related mutations ...

which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement ...

which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement ...

ACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapsed or Refractory Desmoplastic Small Round Cell Tumor: Phase I/II Trial Results This retrospective analysis included patients with cancer who ...

ABSTRACT: Atrial fibrillation (AF) is the most common arrhythmia in clinic. With the increasing aging of the population in China, the incidence of atrial fibrillation is also increasing with age. The ...

SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed ...

We expect to share Phase 2 safety and preliminary efficacy data in H1 2025. APC or AXIN1 Mutant Cancers (REC-4881): Our Phase 2 LILAC clinical trial is an open label, multicenter study of REC-4881 ...

For years, drug developers that apply artificial intelligence (AI) have touted the benefits of the technology—the prospect of speedier development of new treatments at lower cost, thus reducing ...

Recursion delivered multiple data packages to Bayer and initiated the first joint oncology project, which is now expected to advance rapidly towards Lead Series nomination Bayer to become first ...

An open-label, multicenter study investigating RP2 oncolytic immunotherapy in combination with second-line systemic atezolizumab combined with bevacizumab in patients with locally advanced ...

The other features REC-4881 targeting cancers with AXIN1 or APC mutations. Five years is a relatively long time in drug development. It's possible that one or more of these programs could sail ...